araag2/HINT huggingface dataset:
Clinical trial NCT01301508 (phase 2, status: completed)
Conditions: dermatitis, atopic
ICD codes: L20.89, L20.9
Drugs: an2728 ointment, 2%, an2898 ointment, 1%, an2898 ointment vehicle, an2728 ointment vehicle
SMILES: CC1=CC(O)=CC(C)=C1Cl, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical diagnosis of atopic dermatitis that has been clinically stable for ≥1 month

          -  Total body surface area (BSA) of atopic dermatitis involvement ≤35%, excluding
             involvement of the face, scalp, and groin

          -  Presence of two (2) comparable target lesions

          -  Willing and able to apply study medications as directed, comply with study
             instructions, and commit to attending all visits

          -  Females of childbearing potential must use at least one highly effective method of
             birth control. Males with partners of childbearing potential should inform them of
             their participation in this clinical study and use highly effective methods of birth
             control during the study.

        Exclusion Criteria:

          -  Concurrent or recent use of certain topical or systemic medications or phototherapy
             without a sufficient washout period

          -  Active or potentially recurrent dermatologic condition other than atopic dermatitis in
             the target lesion area that may confound evaluation

          -  Significant confounding conditions as assessed by study doctor

          -  History or evidence of allergies requiring acute or chronic treatment (except seasonal
             allergic rhinitis)

          -  Participated in any other trial of an investigational drug or device within 30 days or
             participation in a research study concurrent with this study

          -  Pregnancy or lactation
Clinical trial NCT01267188 (phase 2, status: completed)
Conditions: tardive dyskinesia
ICD codes: K22.4, G24.01
Drugs: nbi-98854
SMILES: COC1=C(OC)C=C2[C@H]3C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN3CCC2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Males or females (non-childbearing potential) aged 18 to 65 years (both inclusive).

          -  Have moderate or severe Tardive Dyskinesia symptoms (Total AIMS score of at least 9)

          -  Have a clinical diagnosis of schizophrenia or schizoaffective disorder.

          -  Receiving a stable dose of antipsychotic medication for a minimum of 30 days or have
             stable psychiatric status.

          -  Doses of concurrent medications and the conditions being treated have been stable for
             a minimum of 30 days and expected to remain stable during the study.

          -  Are in good general health and expected to complete the clinical study as designed.

          -  Have a body mass index (BMI) of 18 to 38 kg/m^2.

          -  Have adequate hearing, vision, and language skills to perform the procedures specified
             in the protocol.

        Exclusion Criteria:

          -  Have an active clinically significant unstable medical condition within 1 month (30
             days) prior to screening.

          -  Have a history of substance dependence or substance (drug) or alcohol abuse within the
             3 months before study start.

          -  Have a known history of neuroleptic malignant syndrome.

          -  Have a significant risk of suicidal or violent behavior.

          -  Receiving medication for the treatment of Tardive Dyskinesia

          -  Receiving any excluded concomitant medication as specified in the protocol.
Clinical trial NCT00422942 (phase 2, status: terminated)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: rituximab [mabthera/rituxan], methotrexate
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Reason stopped: 
    study was terminated after enrollment of 3 participants due to recruitment difficulties.
  
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients 18-80 years of age;

          -  RA for >=3 months;

          -  receiving outpatient treatment;

          -  failed treatment with >=1 DMARD (but not anti TNF or other biologic therapy);

          -  inadequate response to methotrexate, having taken and tolerated it for >=12 weeks,
             with a stable dose for >=4 weeks.

        Exclusion Criteria:

          -  rheumatic autoimmune disease other than RA, or significant systemic involvement
             secondary to RA;

          -  history of, or current, inflammatory joint disease other than RA, or other systemic
             autoimmune disorder;

          -  diagnosis of RA before the age of 16;

          -  bone/joint surgery within 12 weeks of study;

          -  prior use of anti-TNF or other biologic therapy, an anti-alpha 4 integrin, or any
             cell-depleting therapies.
Clinical trial NCT00234702 (phase 2, status: completed)
Conditions: kidney diseases
ICD codes: I12.9, N18.9, Q61.9, I12.0, D63.1, N18.1, N18.5
Drugs: lanthanum carbonate, placebo
SMILES: [La+3].[La+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Under a physician's care for CKD for > 2 months and are not expected to begin dialysis
             for 4 months

          -  Screening estimated GFR of 15-59 mL/1.73 m2

          -  Serum phosphorus >= 4.7 mg/d following washout

        Exclusion Criteria:

          -  Requiring treatment with cinacalcet HCI or compounds containing phosphate, aluminum,
             calcium or magnesium

          -  Rapidly progressing glomerulonephritis

          -  Cirrhosis or other clinically significant liver diseases

          -  Past or present uncontrolled peptic ulcer, Crohn's disease, malignancy or recent GI
             bleed
Clinical trial NCT00279409 (phase 2, status: terminated)
Conditions: attention deficit hyperactivity disorder
ICD codes: F90.2, F90.8, F90.9, F90.0, F90.1
Drugs: aripiprazole, sugar pill
SMILES: ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl, OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O
Reason stopped: 
    recruitment rate too slow
  
Eligibility criteria:

        Inclusion Criteria:

          1. English or Spanish speaking parent/guardian. Parent/guardian and child must be able to
             understand the protocol.

          2. Primary diagnosis of ADHD despite treatment with a stimulant by the primary care
             treatment provider.

          3. Non-responder or partial responder to stimulant treatment. ADHD symptoms and clinical
             impairment despite treatment with stimulant (including OROS-MPH [Concerta] or mixed
             salts amphetamine [Adderall]).

          4. IQ of greater than 70.

          5. The subject must be in school.

          6. The family must be able to attend weekly visits.

        Exclusion Criteria:

          1. Unable to understand protocol or follow study procedures.

          2. Subject doing well on stimulants.

          3. Subjects showing lack of response or minimal response to stimulants due to
             non-compliance with taking medication or taking suboptimal doses.

          4. Autism, Psychosis, Bipolar Disorder, Drug Abuse, significant suicidality, or any other
             psychiatric disorder (such as MDD, Anxiety Disorders, Eating Disorders) in addition to
             ADHD that will require treatment with additional medication or therapy.

          5. The subject is using or abusing recreational drugs or has a positive urine toxicology
             screen (except for stimulants).

          6. The subject has a history of physical, sexual, or emotional abuse that resulted in a
             clinically significant impact on clinical presentation, potentially driving some of
             the symptoms of ADHD.

          7. Females who are pregnant or breast-feeding or who have a positive urine pregnancy
             test.

          8. Sexually active females and males who do not agree to use adequate birth control.

          9. Abnormal cardiac function.

         10. Subject is taking prohibited concomitant medication during phase 1 or phase 2 of the
             trial.
Clinical trial NCT01285752 (phase 2, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: ak106-001616, ak106-001616, active comparator
SMILES: CNC[C@H](O)C1=CC(O)=C(O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of RA (class I to III)

          -  Stable dose of methotrexate (at least 12 weeks)

        Exclusion Criteria:

          -  Pregnant or breastfeeding

          -  Abnormal screening laboratory test values considered to be clinically significant
Clinical trial NCT01052779 (phase 2, status: completed)
Conditions: iron deficiency, anemia, kidney disease
ICD codes: E61.1, D50.8, D50.9, D50.0, D53.2, D64.9, D46.4, D53.0, D53.9, D61.3, D61.9, I12.9, N18.9, Q61.9, I12.0, D63.1, N18.1, N18.5
Drugs: ferumoxytol, iron sucrose
SMILES: COC1=CC=CC=C1OCC(O)CO, O.O.O.[OH-].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O
Eligibility criteria:

        Inclusion Criteria:

        Key Inclusion Criteria include:

          1. Males and females ≥18 years of age

          2. An estimated glomerular filtration rate <60 mL/minute or a diagnosis of CKD (such as
             nephropathy, nephritis)

          3. Hemoglobin <11.0 g/deciliter (dL)

          4. Transferrin saturation <30%

          5. Hemodialysis participants on maintenance dialysis for at least 3 months prior to
             screening and currently receiving dialysis 3 times per week

          6. Female participants of childbearing potential who are sexually active must be on an
             effective method of birth control for at least 1 month prior to screening and agree to
             remain on birth control until completion of the study

        Exclusion Criteria:

        Key Exclusion Criteria include:

          1. History of allergy to IV iron

          2. Allergy to 2 or more classes of drugs

          3. Female participants who are pregnant or intend to become pregnant, breastfeeding,
             within 3 months postpartum, or have a positive serum or urine pregnancy test

          4. Hemoglobin ≤7.0 g/dL

          5. Received another investigational agent within 4 weeks prior to screening, or planned
             receipt of an unspecified investigational agent during the study period

          6. Known causes of anemia other than iron deficiency (such as hemolysis and vitamin B12
             or folate deficiency)
Clinical trial NCT01154985 (phase 2, status: completed)
Conditions: steatohepatitis
ICD codes: K75.81
Drugs: placebo capsule, epa-e 300 mg capsule, epa-e 300 mg capsule
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of definite NASH

          -  Patients with diabetes taking stable doses of anti-diabetic agents are eligible

          -  No significant concomitant medical illness

        Exclusion Criteria:

          -  Diagnosis of cirrhosis.

          -  Serum ALT > 300 U/L

          -  Use of drugs associated with steatohepatitis

          -  Use of the following anit-NASH agents:

               1. Vitamin E > 60 IU per day

               2. Omega-3-acid ethyl esters or omega-3-polyunsaturated fatty acid (PUFA)-containing
                  supplements > 200 mg per day

               3. Thiazolidinediones (e.g. pioglitazone)

          -  Use of non-stable doses of the following anti-NASH agents: HMGCoA reductase inhibitors
             (statins), fibrates, probucol, ezetimibe, ursodiol (UDCA), taurine, betaine,
             N-acetylcysteine, s-adenosylmethionine (SAM-E), milk thistle, anti-TNF therapies, or
             probiotics.

          -  Other liver disease
Clinical trial NCT00382720 (phase 2, status: completed)
Conditions: stomach neoplasms
ICD codes: D13.1, C16.9, C16.1, C16.2, D37.1, C16.8, C16.5
Drugs: docetaxel + oxaliplatin, docetaxel + oxaliplatin + 5-fu, docetaxel + oxaliplatin + capecitabine
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion criteria:

          -  Histologically proven gastric adenocarcinoma, including adenocarcinoma of the
             gastro-oesophageal junction

          -  Metastatic or locally recurrent disease

          -  Prior adjuvant (and/or neo-adjuvant) chemotherapy with 5-Fluorouracil, Cisplatin,
             epirubicin is allowed provided that the patient has relapsed > 12 months after the end
             of the chemotherapy

          -  Performance status Karnofsky index > 70

          -  Hematology within 7 days before randomization:Hemoglobin ≥10g/dl, Absolute Neutrophil
             Count ≥2.0 10^9/L, platelets ≥100 x 10^9/L

          -  Blood chemistry within 7 days before randomization:Total bilirubin ≤1x Upper Normal
             Limit(UNL), Aspartate Aminotransferase (AST) Serum Glutamic Oxaloacetic Transaminase
             SGOT) and Alanine Aminotransferase (ALT)Serum Glutamate Pyruvate Transaminase(SGPT)
             ≤2.5xUNL, alkaline phosphatase ≤ 5x UNL, provided that AST or ALT > 1.5 x UNL is not
             associated with alkaline phosphatase > 2.5 x UNL; creatinine ≤1.25x UNL or 1.25x UNL <
             creatinine ≤1.5x UNL and calculated/measured creatinine clearance ≥60 ml/min)

          -  Measurable and/or evaluable metastatic disease

        Exclusion criteria:

          -  Any prior palliative chemotherapy

          -  Neurosensory symptoms National Cancer Institute Common Toxicity Criteria for Adverse
             Events grade≥2

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT01796964 (phase 2, status: completed)
Conditions: exudative age-related macular degeneration
ICD codes: H35.3230, H35.3210, H35.3220, H35.3233, H35.3290, H35.3213, H35.3223
Drugs: esba1008 solution, aflibercept
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Give written informed consent; be able to make the required study visits and follow
             instructions.

          -  Diagnosis of wet age-related macular degeneration, as specified in protocol.

          -  Best-corrected visual acuity (BCVA) as specified in protocol

          -  Other protocol-specified inclusion criteria may apply.

        Exclusion Criteria:

          -  Either eye: Any active ocular or periocular infection or active intraocular
             inflammation.

          -  Study eye: Any approved or investigational treatment for exudative AMD other than
             vitamin supplements.

          -  Study eye: Any current or history of macular or retinal disease other than exudative
             AMD.

          -  Study eye: Any concurrent intraocular condition that, in the opinion of the
             Investigator, could require medical or surgical intervention during the course of the
             study to prevent or treat vision loss, or that limits the potential to gain visual
             acuity with the investigational product.

          -  Study eye: Uncontrolled glaucoma.

          -  Study eye: Any ocular disease that, in the opinion of the Investigator, could
             compromise the visual acuity.

          -  Study eye: History of eye surgery, as specified in protocol.

          -  Study eye: Use of corticosteroids, as specified in protocol.

          -  Any medical condition that, in the opinion of the Investigator, would preclude
             scheduled study visits, completion of the study or safe administration of
             investigational product.

          -  Any screening laboratory result that, in the opinion of the Investigator, would make
             the patient unsuitable for study participation.

          -  History of hypersensitivity to any component used in the study, as assessed by the
             Investigator.

          -  Women of childbearing potential: Lactating, pregnant, plan to become pregnant, or not
             using adequate birth control, as specified in protocol.

          -  Participation in an investigational drug or device study within time period specified
             in protocol.

          -  Other protocol-defined exclusion criteria may apply.
Clinical trial NCT00381719 (phase 2, status: completed)
Conditions: diabetic neuropathy, painful
ICD codes: G58.0, G61.1, A52.15, G60.3, G61.82, H46.2, H46.3
Drugs: agn 203818, agn 203818, agn 203818, placebo capsule
SMILES: C[C@H](C1=CNC(=S)N1)C1=C(C)C(C)=CC=C1, C[C@H](C1=CNC(=S)N1)C1=C(C)C(C)=CC=C1, C[C@H](C1=CNC(=S)N1)C1=C(C)C(C)=CC=C1, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of diabetic peripheral neuropathy

          -  Moderate to severe neuropathic pain

        Exclusion Criteria:

          -  Any other uncontrolled disease

          -  Pregnant or nursing females
Clinical trial NCT01491529 (phase 2, status: completed)
Conditions: dyskinesias, parkinson disease, movement disorders, parkinsonian disorders, anti-dyskinesia agents
ICD codes: G20, G47.61, G25.70, G25.9, H51.9, F98.4, G25.79, G25.89
Drugs: afq056, placebo
SMILES: COC(=O)N1CC[C@@H]2[C@H]1CCC[C@@]2(O)C#CC1=CC(C)=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males and Females 30-80 years old

          -  Use of highly effective methods of contraception during study in women of childbearing
             potential

          -  Outpatients

          -  Clinical diagnosis of Parkinson's Disease according to UK Parkinson's Disease Society
             Brain Bank Clinical Diagnosis criteria

          -  Score of >/= 2 on UPDRS items 32 and 33

          -  Dyskinesias for at least 3 months before baseline

          -  On stable treatment regimen with L-dopa and other anti-parkinsonian treatment for 4
             weeks prior to baseline

          -  Demonstrate capacity to complete accurate diary ratings

          -  Patients who have a primary caregiver willing to assess the condition of the patient
             throughout the study in accordance with protocol requirements

          -  Group 2 only: Patients must be on a stable and well tolerated dose of amantadine for
             at least 4 weeks prior to BL1 and must maintain the stable dose of amantadine during
             the remainder of the study

        Exclusion Criteria:

          -  Atypical/secondary form of Parkinson's disease

          -  History of surgical treatment of PD, including deep brain stimulation

          -  A score of 5 in the "ON"- state on the Modified Hoehn and Yahr scale

          -  Advanced, severe, or unstable disease other than PD

          -  Evidence of dementia

          -  Treatment with certain prohibited medications

          -  Amantadine within 2 weeks prior to BL1 visit (applies to Group 1 only)

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT00444535 (phase 2, status: completed)
Conditions: neoplasms, breast
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: lapatinib, bevacizumab
SMILES: CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion criteria:

          -  Females that are at least 18 years of age.

          -  Women of childbearing potential must have a negative serum pregnancy test at
             screening.

          -  Documented evidence of HER2-overexpressing unresectable or metastatic breast cancer.
             Disease may/may not have been treated in metastatic setting.

          -  Subjects are permitted (but not required) to have previously-treated brain metastases
             that are stable and asymptomatic.

          -  Adequate hepatic, renal and cardiac function

          -  ECOG score 0-1 and a life expectancy of at least 12 weeks.

          -  Able to swallow oral medication

          -  Signed informed consent

        Exclusion criteria:

          -  Pregnancy

          -  Unstable or symptomatic CNS metastases

          -  Major surgery within 28 days of enrollment (minor surgery within 7 days).

          -  Prior anti-cancer treatment within 14 days of enrollment, or unresolved
             treatment-related toxicities.

          -  A serious non-healing wound, ulcer, or bone fracture at baseline.

          -  Class II, III or IV heart failure as defined by the NYHA functional classification
             system

          -  History of significant vascular disease, arterial thrombosis, unstable INR,
             hypertensive crisis, or uncontrolled hypertension.

          -  History of myocardial infarction, stenting procedure, or angioplasty within 6 months
             of enrollment.

          -  History of abdominal fistulae, gastrointestinal perforation, or intra-abdominal
             abscess within 6 months of enrollment.

          -  History of malabsorption syndrome, ulcerative colitis, or bowel obstruction.

          -  Proteinuria

          -  Requires concurrent anti-cancer treatment or investigational treatment.

          -  Known hypersensitivity to either study medication

          -  Received investigational treatment within 28 days or 5 half-lives, whichever is longer

          -  Concurrent disease or circumstances that would lead the investigator would consider
             the subject an inappropriate candidate for the study

          -  Requires medication that has been excluded during study participation
Clinical trial NCT00041756 (phase 2, status: completed)
Conditions: osteoarthritis, knee
ICD codes: M17.9, M17.0, M17.10, M17.11, M17.12, M17.2, M17.30
Drugs: pg-530742, placebo, 50 mg pg-530742, 100 mg pg-530742, 200 mg pg-530742
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  mild to moderate knee osteoarthritis confirmed by a radiographic technique.

        Exclusion Criteria:

          -  secondary knee osteoarthritis;

          -  diseases other than osteoarthritis that could cause knee pain;

          -  any disease or intervention (surgery, intra-articular injection) that would have an
             impact on knee pain or mobility;

          -  drugs that act potentially on the bone or cartilage component of the knee joint.
Clinical trial NCT00389168 (phase 2/phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: irbesartan, atenolol
SMILES: CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1, CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  At least 18 ys old

          -  Male or female with no child bearing potential

          -  Seated blood pressure diastolic 90-115 mm Hg

          -  Left ventricular mass above 131 g/m2 for men, above 100 g/m2 for women

          -  Informed consent

        Exclusion Criteria:

          -  Coronary artery disease, heart failure or other significant cardiac disorder

          -  Cerebrovascular accident within the past 6 months

          -  A seated systolic blood pressure above 200 mm Hg

          -  Significant renal disease, collagen or vascular disease, or gastrointestinal condition

          -  Significant allergy or intolerance to study drug

          -  Alcohol or drug abuse

          -  Uncontrolled diabetes mellitus